CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $736 | -19.8% | 16,208 | -1.0% | 0.04% | -14.0% |
Q2 2023 | $918 | +29.5% | 16,366 | +4.4% | 0.04% | +22.9% |
Q1 2023 | $709 | +10.6% | 15,674 | -0.6% | 0.04% | +2.9% |
Q4 2022 | $641 | -99.9% | 15,772 | +0.9% | 0.03% | -41.4% |
Q3 2022 | $1,022,000 | +6.1% | 15,639 | -1.3% | 0.06% | +16.0% |
Q2 2022 | $963,000 | +262.0% | 15,844 | +274.7% | 0.05% | +354.5% |
Q1 2022 | $266,000 | +1.9% | 4,229 | +22.8% | 0.01% | +10.0% |
Q4 2021 | $261,000 | -42.6% | 3,443 | -15.3% | 0.01% | -50.0% |
Q3 2021 | $455,000 | -35.6% | 4,066 | -6.8% | 0.02% | -35.5% |
Q2 2021 | $706,000 | +22.8% | 4,363 | -7.6% | 0.03% | +6.9% |
Q1 2021 | $575,000 | -63.5% | 4,723 | -54.1% | 0.03% | -66.7% |
Q4 2020 | $1,575,000 | +109.7% | 10,282 | +14.6% | 0.09% | +81.2% |
Q3 2020 | $751,000 | +17.9% | 8,972 | +3.6% | 0.05% | +4.3% |
Q2 2020 | $637,000 | +91.9% | 8,664 | +10.6% | 0.05% | +64.3% |
Q1 2020 | $332,000 | -36.5% | 7,831 | -8.8% | 0.03% | -22.2% |
Q4 2019 | $523,000 | – | 8,589 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |